Pasithea Therapeutics (KTTA) Income from Continuing Operations (2021 - 2026)
Pasithea Therapeutics (KTTA) posted Income from Continuing Operations of 2869482.0 for Q1 2026, up 71.62% sequentially from 10110868.0 in Q4 2025, and up 19.47% YoY from 2401846.77 in Q1 2025.
Pasithea Therapeutics (KTTA) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Income from Continuing Operations for 6 years, with the latest figure at 2869482.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 19.47% year-over-year to 2869482.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 19733927.0 (down 45.03% YoY) and the FY2025 annual result came in at 20427683.0, down 46.91% from the prior year.
- Income from Continuing Operations grew to 2869482.0 in Q1 2026 per KTTA's latest filing, from 10110868.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1574240.0 in Q1 2022 and troughed at 10110868.0 in Q4 2025.
- A 5-year average of 3920349.94 and a median of 3598084.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations tumbled 912.15% in 2022, then jumped 36.84% in 2024.
- Over 5 years, Income from Continuing Operations stood at 5117688.0 in 2022, then advanced by 1.69% to 5031264.0 in 2023, then surged by 36.84% to 3177661.0 in 2024, then slumped by 218.19% to 10110868.0 in 2025, then jumped by 71.62% to 2869482.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 2869482.0, 10110868.0, and 3037420.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - | -5.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.87 Mn |
| Dec 31, 2025 | -10.11 Mn |
| Sep 30, 2025 | -3.04 Mn |
| Jun 30, 2025 | -3.72 Mn |
| Mar 31, 2025 | -3.56 Mn |
| Dec 31, 2024 | -3.18 Mn |
| Sep 30, 2024 | -3.00 Mn |
| Jun 30, 2024 | -3.87 Mn |
| Mar 31, 2024 | -3.86 Mn |
| Dec 31, 2023 | -5.03 Mn |
| Sep 30, 2023 | -3.61 Mn |
| Jun 30, 2023 | -3.60 Mn |
| Mar 31, 2023 | -3.27 Mn |
| Dec 31, 2022 | -5.12 Mn |
| Sep 30, 2022 | -4.59 Mn |
| Jun 30, 2022 | -2.66 Mn |
| Mar 31, 2022 | -1.57 Mn |
| Dec 31, 2021 | 630,143.00 |
| Sep 30, 2021 | -1.53 Mn |
| Jun 30, 2021 | -727,947.00 |